Zobrazeno 1 - 10
of 371
pro vyhledávání: '"Ron H.N. van Schaik"'
Autor:
Stefan A.J. Buck, Marinda Meertens, Frederiek M.F. van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J.H. Coenen, Andries M. Bergman, Stijn L.W. Koolen, Ronald de Wit, Alwin D.R. Huitema, Ron H.N. van Schaik, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 169, Iss , Pp 115890- (2023)
Extragonadal androgens play a pivotal role in prostate cancer disease progression on androgen receptor signaling inhibitors (ARSi), including abiraterone and enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal
Externí odkaz:
https://doaj.org/article/6d3d5ec4ff3b487a8575fbe70cc76c22
Autor:
G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101955- (2023)
Summary: Background: Central nervous system (CNS) metastases are present in approximately 40% of patients with metastatic epidermal growth factor receptor-mutated (EGFRm+) non-small cell lung cancer (NSCLC). The EGFR-tyrosine kinase inhibitor osimert
Externí odkaz:
https://doaj.org/article/3a9954ccf1454c0c889fa14273839a4e
Autor:
Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Mathias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 160, Iss , Pp 114369- (2023)
Background: Tamoxifen is important in the adjuvant treatment of breast cancer. A plasma concentration of the active metabolite endoxifen of > 16 nM is associated with a lower risk of breast cancer-recurrence. Since inter-individual variability is hig
Externí odkaz:
https://doaj.org/article/2396b06ab4c94959a7fe50d0e9284b90
Autor:
Mirjam de With, Leni van Doorn, Demi C. Maasland, Tessa A.M. Mulder, Esther Oomen-de Hoop, Bianca Mostert, Marjolein Y.V. Homs, Samira El Bouazzaoui, Ron H.J. Mathijssen, Ron H.N. van Schaik, Sander Bins
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114232- (2023)
Aim of the study: Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and can severely decrease quality of life. In this study, we investigated whet
Externí odkaz:
https://doaj.org/article/22d712ca5f2d4b6f9d5ea8fc0cd5da1f
Autor:
Melinda A. Pruis, G.D. Marijn Veerman, H. Carlijne Hassing, Daan A.C. Lanser, Marthe S. Paats, Ron H.N. van Schaik, Ron H.J. Mathijssen, Olivier Manintveld, Anne-Marie C. Dingemans
Publikováno v:
JACC: CardioOncology. 5:102-113
Autor:
Ron H.N. van Schaik, Ron H.J. Mathijssen, Jaap Verweij, Erik A.C. Wiemer, Ferry A.L.M. Eskens, Frederike K. Engels, Peter de Bruijn, Pleun J. de Raaf, Bronno van der Holt, Lena E. Friberg, Alex Sparreboom, Jason A. Sprowl, Laure Elens, Anne-Joy M. de Graan
Purpose: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure and toxicity. Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b025f2e24135406f2ebf1a1fbaa683f
https://doi.org/10.1158/1078-0432.c.6520802
https://doi.org/10.1158/1078-0432.c.6520802
Autor:
Ron H.N. van Schaik, Ron H.J. Mathijssen, Jaap Verweij, Erik A.C. Wiemer, Ferry A.L.M. Eskens, Frederike K. Engels, Peter de Bruijn, Pleun J. de Raaf, Bronno van der Holt, Lena E. Friberg, Alex Sparreboom, Jason A. Sprowl, Laure Elens, Anne-Joy M. de Graan
PDF file - 45K, Hardy Weinberg equilibrium.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec40f1a9bdd542536d9278b6920efa6
https://doi.org/10.1158/1078-0432.22446617.v1
https://doi.org/10.1158/1078-0432.22446617.v1
Autor:
Ron H.N. van Schaik, Ron H.J. Mathijssen, Jaap Verweij, Erik A.C. Wiemer, Ferry A.L.M. Eskens, Frederike K. Engels, Peter de Bruijn, Pleun J. de Raaf, Bronno van der Holt, Lena E. Friberg, Alex Sparreboom, Jason A. Sprowl, Laure Elens, Anne-Joy M. de Graan
PDF file - 244K, Amplification plot.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d536128cf5bba8afd9055da2f08c3c9
https://doi.org/10.1158/1078-0432.22446620
https://doi.org/10.1158/1078-0432.22446620
Autor:
Sophie M. Ernst, Ronald van Marion, Peggy N. Atmodimedjo, Evert de Jonge, Ron H. Mathijssen, Marthe S. Paats, Peter de Bruijn, Ron H.N. van Schaik, Hendrikus J. Dubbink, Anne-Marie C. Dingemans
Publikováno v:
Cancer Research. 83:2137-2137
Introduction: The CodeBreaK 200 trial showed that in patients (pts) with advanced KRAS G12C mutated (KRAS+) NSCLC sotorasib, a KRAS G12C-specific inhibitor, is superior to docetaxel for progression free survival (PFS) (HR 0.66) with a one-year PFS of
Autor:
Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A.L.M. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Sander Bins, Anna M.J. Thijs, Marjan M.J. Laven, Anke M. Hövels, Saskia A.C. Luelmo, Danny Houtsma, Katerina Shulman, Howard L. McLeod, Ron H.N. van Schaik, Henk-Jan Guchelaar, Ron H.J. Mathijssen, Hans Gelderblom, Maarten J. Deenen
Publikováno v:
European Journal of Cancer, 162, 148-157. Elsevier Ltd.
European Journal of Cancer, 162, 148-157. ELSEVIER SCI LTD
European Journal of Cancer, 162, 148-157. ELSEVIER SCI LTD
Aim: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan.Patients and methods: In this prospective, multicentre, non-randomised study, patients intended for treatment with irinotecan were pr